Study of BMB-101 for people with Prader-Willi syndrome
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an experimental drug called BMB-101 to see if it can help reduce the constant hunger (hyperphagia) that is common in Prader-Willi syndrome. The trial will check how safe and effective the drug is, and if it works, it may offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You need a confirmed genetic diagnosis of Prader-Willi syndrome.
- You must have moderate to severe hyperphagia, measured by a standard scale.
- If you take growth hormone, you must have been on a stable dose for at least 90 days before the study starts.
- You must not have certain heart, liver, or kidney problems.
- You must be willing to use effective birth control during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called CSTI-500 for people with Prader-Willi syndrome who are in the hyperphagia (constant hunger) phase. It aims to see if the drug can improve behavior and reduce overeating. You and your caregiver will need to visit the clinic regularly and answer questions about symptoms.
This trial studies whether taking prebiotics and probiotics can help children with Prader-Willi syndrome manage obesity. It’s testing a gut-focused approach to weight control over the study period.
This study tests whether giving growth hormone to adults with Prader-Willi syndrome can improve their health and well-being. The goal is to see if the treatment is safe and helpful for adults with this condition.
This study tests an oral medication, pitolisant, in people with Prader-Willi syndrome who have already been in a pitolisant study. It aims to see if continuing treatment is safe and effective.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
This study follows people with Prader-Willi syndrome who are already taking or starting VYKAT XR, including those switching from an earlier version of the drug (DCCR). It aims to understand how the treatment works in everyday life.
Hear when a new Prader-Willi Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.